Welcome to our dedicated page for Replimune Group news (Ticker: REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.
Replimune Group, Inc. (Nasdaq: REPL) generates frequent news as a clinical stage biotechnology company developing novel oncolytic immunotherapies based on its proprietary HSV‑1‑derived RPx platform. Headquartered in Woburn, Massachusetts and founded in 2015, the company focuses on product candidates such as RP1 (vusolimogene oderparepvec) and RP2, which are being studied across multiple difficult‑to‑treat cancers.
News related to Replimune commonly covers clinical trial updates from programs like IGNYTE, IGNYTE‑3, ARTACUS and REVEAL. These updates include data presentations at major medical meetings, such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress, where the company has reported biomarker findings, response rates, durability of responses and safety data for RP1 plus nivolumab in advanced melanoma and non‑melanoma skin cancers.
Another major category of news involves regulatory milestones. Replimune has announced the FDA’s Complete Response Letter for the Biologics License Application (BLA) for RP1 in combination with nivolumab in advanced melanoma, subsequent Type A meetings with the FDA, and the agency’s acceptance of a BLA resubmission with a specified PDUFA target action date. These items are closely followed by investors and the oncology community because they reflect the evolving regulatory path for RP1.
Replimune’s news flow also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, and equity‑based inducement grants to employees, as well as participation in investor conferences like the J.P. Morgan Healthcare Conference. Together, these announcements provide insight into the company’s operational progress, clinical development priorities and interactions with regulators.
Investors, clinicians and other stakeholders can use this news feed to track key developments around Replimune’s RPx platform, its lead programs in advanced melanoma and skin cancers, and the broader pipeline in metastatic uveal melanoma, hepatocellular carcinoma and biliary tract cancer.
Replimune Group announced inducement equity awards to 12 newly hired non-executive employees. The awards include non-qualified stock options to purchase 19,390 shares at $12.02 per share and restricted stock units representing 38,810 shares. The options have a 10-year term with 25% vesting after one year and the remainder monthly over three years. The restricted stock units vest in four annual installments starting November 15, 2025. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and align with the Company's 2018 Equity Incentive Plan terms.
Replimune Group (NASDAQ: REPL) announced two key presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) in Houston, Texas. The first is a late-breaking oral presentation featuring primary analysis data from the IGNYTE clinical trial, including subgroup and initial biomarker analyses of RP1 plus nivolumab in anti-PD1 failed melanoma patients. Dr. Michael K. Wong from MD Anderson Cancer Center will present this on November 9, 2024.
Additionally, Dr. Diwakar Davar from UPMC Hillman Cancer Center will present an encore poster on November 8, 2024, sharing data from the ARTACUS clinical trial, which studied RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies.
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company, has announced the grant of inducement equity awards to 9 newly hired non-executive employees. The awards include:
- Non-qualified stock options to purchase 8,870 shares of common stock
- Restricted stock units representing 17,745 shares of common stock
The stock options have an exercise price of $11.33 per share, equal to the closing price on October 7, 2024. They have a 10-year term and will vest over four years. The restricted stock units vest in approximately four equal annual installments beginning on November 15, 2025.
These inducement awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4) and will have terms consistent with the Company's 2018 Equity Incentive Plan.
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced its participation in two upcoming investor conferences. The company's management team will be presenting and hosting investor meetings at these events:
1. BMO 2024 Oncology Summit on Tuesday, October 8, 2024
2. 3rd Annual Roth Healthcare Opportunities Conference on Wednesday, October 9, 2024
These conferences provide Replimune with an opportunity to showcase its progress in the field of oncolytic immunotherapies and engage with investors. The company's presence at these events underscores its commitment to advancing its clinical-stage pipeline and maintaining open communication with the investment community.
Replimune Group (NASDAQ: REPL) presented primary analysis data from the IGNYTE clinical trial of RP1 combined with nivolumab in anti-PD1 failed melanoma at ESMO Congress 2024. The trial included 140 patients who received RP1 plus nivolumab after confirmed progression on anti-PD1 based therapy. Key results include:
- Overall response rate (ORR) of 33.6% by mRECIST and 32.9% by RECIST 1.1
- Complete response rate of 15% by mRECIST
- ORR of 27.7% in patients with prior anti-PD1 and anti-CTLA-4 treatment
- Median duration of response from treatment initiation was 27.6 months
- One-, two-, and three-year survival rates were 75.3%, 63.3%, and 54.8% respectively
The treatment was well-tolerated with mostly Grade 1-2 adverse events. Replimune plans to submit a BLA for RP1 in anti-PD1 failed melanoma in the second half of 2024.
Replimune Group, Inc. (NASDAQ: REPL) has successfully completed a pre-Biologics License Application (pre-BLA) meeting with the FDA, supporting their plans to submit a BLA for RP1 (vusolimogene oderparepvec) in the treatment of anti-PD1 failed melanoma via the accelerated approval pathway in 2H 2024. The company's CEO, Sushil Patel, confirmed that the accelerated approval path is available for RP1 in this indication. Topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab showed an overall response rate of 33%. Independently reviewed data from this trial, including key secondary endpoints and subgroup analyses, will be presented at the ESMO Annual Congress 2024 in Barcelona on September 15, 2024.
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company, announced the election of Madhavan (Madhu) Balachandran to its Board of Directors at the annual stockholders meeting. Balachandran brings over 40 years of experience in manufacturing and operations to Replimune's board. He previously served as Executive Vice President of Operations at Amgen Inc., overseeing global operations. CEO Sushil Patel expressed enthusiasm about Balachandran's addition, citing his valuable experience in commercial development, manufacturing, and operations as assets for Replimune's commercialization preparations. Balachandran's background includes senior operations positions at Burroughs Wellcome Co. and an extensive educational background in chemical engineering and business administration.
Replimune Group (NASDAQ: REPL) announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The presentation, titled 'Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab,' will be delivered by Dr. Caroline Robert from Gustave Roussy Cancer Center on September 15, 2024. This presentation is part of the Mini Oral Session on Melanoma and other skin tumors, highlighting Replimune's progress in developing novel oncolytic immunotherapies.
Replimune Group, Inc. (NASDAQ: REPL) has initiated the IGNYTE-3 study, a global Phase 3 clinical trial evaluating RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma patients who have progressed on anti-PD1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment. The trial, which has dosed its first patient, aims to support global regulatory interactions and confirm clinical benefits reported in the Phase 2 IGNYTE cohort. With 400 patients enrolled, the study will compare RP1 plus nivolumab against physician's choice treatments, focusing on overall survival as the primary endpoint. Secondary endpoints include progression-free survival and objective response rate. This trial is important for Replimune's planned BLA submission for RP1 in advanced melanoma later this year.
Replimune Group (NASDAQ: REPL) reported fiscal Q1 2025 results and provided a corporate update. Key highlights include:
- Pre-BLA meeting with FDA scheduled for September, BLA submission planned for 2H 2024
- First patient enrollment in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in Q3 2024
- Protocol finalized for registration-directed study of RP2 in uveal melanoma
- Completed PIPE financing raising $96.7 million net
- Cash position of $469.1 million as of June 30, 2024
- R&D expenses increased to $43.0 million for Q1 2025
- Net loss of $53.8 million for Q1 2025
The company believes its current cash position will fund operations into the second half of 2026, including RP1 commercialization scale-up.